NRIX

MKT CAP:$1B

Nurix Therapeutics, Inc.

Market Cap

$1B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$16.77-$1.29 (-7.12%)

Apr 24, 2026

Company Details

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally availa...

CEO

Arthur T. Sands

IPO Date

Jul 24, 2020

Website

www.nurixtx.com

Key Metrics TTM

Revenue

$72M

+27.2% YoY

Net Income

-$295M

EPS (Diluted)

-$3.16

Free Cash Flow

-$272M

Revenue / Share

$0.65

Gross Margin

-139.4%

Operating Margin

-439.3%

Net Margin

-411.4%

FCF Margin

-378.7%

P/S

20.2x

P/E

—

Earnings Reports

Q1 2026

Apr 8, 2026

$6M-66.1%EPS -$0.79

FY 2025

Jan 28, 2026

$84M+54.0%EPS -$3.05

Q4 2025

Jan 28, 2026

$14M+2.2%EPS -$0.82

Q3 2025

Oct 9, 2025

$8M-37.3%EPS -$1.03

Q2 2025

Jul 9, 2025

$44M+264.3%EPS -$0.52

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q2 22	$11M	-$36M	-$46M
Q3 22	$11M	-$37M	-$47M
Q4 22	$7M	-$39M	-$49M
Q1 23	$13M	-$33M	-$43M
Q2 23	$31M	-$15M	-$27M
Q3 23	$18M	-$29M	-$40M
Q4 23	$15M	-$35M	-$45M
Q1 24	$17M	-$33M	-$45M
Q2 24	$12M	-$37M	-$49M
Q3 24	$13M	-$43M	-$55M
Q4 24	$13M	-$54M	-$65M
Q1 25	$18M	-$51M	-$63M
Q2 25	$44M	-$34M	-$48M
Q3 25	$8M	$3M	-$91M
Q4 25	$14M	$9M	-$83M
Q1 26	$6M	-$78M	-$92M

Valuation

Quarter	P/S	P/E
Q2 22	13.9x	—
Q3 22	20.5x	—
Q4 22	15.9x	—
Q1 23	11.6x	—
Q2 23	9.8x	—
Q3 23	6.8x	—
Q4 23	4.2x	—
Q1 24	7.6x	—
Q2 24	18.7x	—
Q3 24	33.1x	—
Q4 24	32.9x	—
Q1 25	21.0x	—
Q2 25	11.5x	—
Q3 25	9.7x	—
Q4 25	16.9x	—
Q1 26	20.9x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q2 22	-$33M	-$36M
Q3 22	-$46M	-$50M
Q4 22	-$38M	-$41M
Q1 23	-$48M	-$51M
Q2 23	-$18M	-$20M
Q3 23	-$41M	-$44M
Q4 23	$27M	$24M
Q1 24	-$42M	-$45M
Q2 24	-$40M	-$42M
Q3 24	-$42M	-$45M
Q4 24	-$49M	-$51M
Q1 25	-$61M	-$65M
Q2 25	-$63M	-$66M
Q3 25	-$57M	-$60M
Q4 25	-$68M	-$73M
Q1 26	-$72M	-$73M

Capital Expenditures

Quarter	CapEx
Q2 22	$3M
Q3 22	$3M
Q4 22	$3M
Q1 23	$2M
Q2 23	$1M
Q3 23	$2M
Q4 23	$3M
Q1 24	$3M
Q2 24	$2M
Q3 24	$2M
Q4 24	$2M
Q1 25	$3M
Q2 25	$3M
Q3 25	$3M
Q4 25	$5M
Q1 26	$1M

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q2 22	+61.2%	+70.6%
Q3 22	+5.3%	+46.5%
Q4 22	-8.3%	+22.3%
Q1 23	+31.8%	+6.2%
Q2 23	+168.3%	+0.5%
Q3 23	+71.1%	+1.7%
Q4 23	+123.5%	+9.0%
Q1 24	+30.7%	+11.1%
Q2 24	-60.6%	+5.6%
Q3 24	-31.8%	+14.9%
Q4 24	-12.4%	+28.8%
Q1 25	+11.3%	+31.6%
Q2 25	+264.3%	+52.4%
Q3 25	-37.3%	+47.7%
Q4 25	+2.2%	+24.0%
Q1 26	-66.1%	+21.4%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q2 22	$7M	59.3%
Q3 22	$7M	64.8%
Q4 22	$8M	122.3%
Q1 23	$8M	66.9%
Q2 23	$9M	28.4%
Q3 23	$8M	45.7%
Q4 23	$8M	52.9%
Q1 24	$8M	47.2%
Q2 24	$9M	73.1%
Q3 24	$9M	69.5%
Q4 24	$9M	64.0%
Q1 25	$9M	47.3%
Q2 25	$10M	23.6%
Q3 25	$10M	123.8%
Q4 25	$0	0.0%
Q1 26	$0	0.0%

OpEx Breakdown

Quarter	R&D	G&A
Q2 22	$47M	$10M
Q3 22	$48M	$10M
Q4 22	$46M	$9M
Q1 23	$46M	$10M
Q2 23	$46M	$12M
Q3 23	$48M	$11M
Q4 23	$50M	$11M
Q1 24	$50M	$12M
Q2 24	$49M	$12M
Q3 24	$55M	$12M
Q4 24	$67M	$11M
Q1 25	$70M	$12M
Q2 25	$78M	$14M
Q3 25	$86M	$13M
Q4 25	$81M	$14M
Q1 26	—	$15M

Revenue Segments

Quarter	Collaboration Revenue	License Revenue
Q3 23	$18M	—
Q2 24	$12M	—
Q3 24	$13M	—
Q2 25	$14M	$30M
Q3 25	$8M	—
Q1 26	$6M	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q2 22	$42M	$256M	$297M
Q3 22	$48M	$297M	$344M
Q4 22	$64M	$245M	$309M
Q1 23	$34M	$244M	$277M
Q2 23	$59M	$222M	$281M
Q3 23	$42M	$217M	$259M
Q4 23	$55M	$233M	$288M
Q1 24	$50M	$194M	$244M
Q2 24	$117M	$326M	$443M
Q3 24	$99M	$349M	$448M
Q4 24	$110M	$500M	$610M
Q1 25	$76M	$474M	$550M
Q2 25	$84M	$402M	$486M
Q3 25	$78M	$350M	$429M
Q4 25	$247M	$346M	$593M
Q1 26	$71M	$470M	$541M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q2 22	45M	+0.5%	+2.5%
Q3 22	51M	+13.3%	+14.6%
Q4 22	54M	+6.0%	+21.1%
Q1 23	54M	+0.2%	+20.9%
Q2 23	54M	+0.4%	+20.8%
Q3 23	54M	+0.2%	+6.9%
Q4 23	55M	+0.5%	+1.3%
Q1 24	55M	+0.4%	+1.6%
Q2 24	62M	+13.6%	+15.0%
Q3 24	73M	+16.7%	+33.8%
Q4 24	78M	+7.7%	+43.4%
Q1 25	84M	+6.6%	+52.2%
Q2 25	84M	+0.4%	+34.5%
Q3 25	84M	+0.3%	+15.6%
Q4 25	95M	+13.0%	+21.3%
Q1 26	110M	+15.8%	+31.7%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q2 22	$47.2K	242
Q3 22	$44.6K	242
Q4 22	$22.8K	297
Q1 23	$42.7K	297
Q2 23	$103.3K	297
Q3 23	$62.2K	297
Q4 23	$53.4K	284
Q1 24	$58.4K	284
Q2 24	$42.6K	284
Q3 24	$44.3K	284
Q4 24	$46.4K	286
Q1 25	$64.5K	286
Q2 25	$154.0K	286
Q3 25	$27.6K	286
Q4 25	$68	200K
Q1 26	$31	200K

Revenue / Employee